Asset
GRANISETRON
Heron Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02106494 | phase3 | completed | 2014-03-01 | 2015-05-01 | Heron Therapeutics | A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC |
| NCT00343460 | phase3 | completed | 2006-06-01 | 2008-09-01 | Heron Therapeutics | APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer |
| NCT05434663 | phase4 | unknown | 2022-07-06 | 2025-10-01 | Heron Therapeutics | Safety Study of Repeat Doses of SUSTOL in Adults |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 022445 | NDA | HERON THERAPEUTICS INC |
Marketed products (1)
- SUSTOL